Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FT14 Conditioning for Allo-SCT in AML
NCT07232953Phase 2Active, not recruiting
- Sponsor
- ASST Spedali Civili di Brescia
- Start
- Nov 2022
- Primary completion
- Jun 2026
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of treosulfan in acute myeloid leukemia (AML), sponsored by ASST Spedali Civili di Brescia. Started Nov 2022; status: active, not recruiting.
02
Drugs
treosulfan
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07232953.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07232953.